Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 first-line advanced clear cell renal cell carcinoma trial of pembrolizumab + belzutifan + lenvatinib or MK-1308A + lenvatinib versus pembrolizumab + lenvatinib
CTR20220530Phase 3Terminated
- Sponsor
- MSD
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of belzutifan in clear cell renal cell carcinoma (ccRCC), sponsored by MSD. Started Aug 2022; status: terminated.
02
Drugs
belzutifan
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on CTR20220530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220530.